07:00 , Jul 1, 2013 |  BC Week In Review  |  Clinical News

DM-199: Phase II started

DiaMedica started the Phase II portion of a Dutch Phase I/II trial after completing dosing of DM-199 in 18 healthy volunteers in the Phase I portion. The company said preliminary data from the Phase I...
07:00 , Apr 15, 2013 |  BC Week In Review  |  Clinical News

DM-199: Phase I/II started

DiaMedica began a Dutch Phase I/II trial of DM-199. The Phase I portion will evaluate single and multiple ascending-doses of DM-199 in 36 healthy volunteers. The Phase II portion in 40 Type II diabetics will...
08:00 , Nov 15, 2010 |  BC Week In Review  |  Clinical News

DiaMedica preclinical data

In a rat model of Type II diabetes, a single dose of DM-199 led to a 122% increase in maximal glucose infusion rate compared to untreated controls, which allowed the DM-199-treated rats to process 77%...
07:00 , Aug 9, 2010 |  BC Week In Review  |  Clinical News

DiaMedica preclinical data

In a collagen-induced animal model of RA, DM-99 significantly reduced joint swelling by up to 90% vs. control (p<0.001). Furthermore, a single dose of the undisclosed naturally occurring protein that inhibits glycogen synthase kinase 3...
07:00 , Aug 9, 2010 |  BC Week In Review  |  Clinical News

DiaMedica preclinical data

In a delayed hypersensitivity model, a single dose of DM-99 significantly reduced skin inflammation by 67% vs. control (p<0.05). Furthermore, skin inflammation following a single dose of the undisclosed naturally occurring protein that inhibits glycogen...
07:00 , Aug 9, 2010 |  BC Week In Review  |  Clinical News

DiaMedica preclinical data

In a mouse model of Type I diabetes, twice-daily DM-99 significantly reduced fasting plasma glucose (FPG) by 68% compared with untreated control mice at day 21 (p=0.05). The undisclosed naturally occurring protein that inhibits glycogen...